|
|
|
|
Mailing Address:
Harvard Medical School
Department of Ambulatory Care and Prevention
133 Brookline Avenue, 6th Floor
Boston, MA 02215
Email:
Anita_Wagner@hms.harvard.edu
Phone: (617) 509-9956
Fax: (617) 859-8112
Staff Assistant: Joyce Cheatham
Websites:
|
|
|
Anita Wagner, PharmD, MPH, DrPH
|
Dr. Wagner is an Assistant Professor in the Department of Ambulatory Care and Prevention (DACP) at Harvard Medical School and Harvard Pilgrim Health Care. She is a member of DACP's Drug Policy Research Group and of the WHO Collaborating Center in Pharmaceutical Policy (WHO CCPP) formed jointly by the DACP and the Center for International Health and Development at Boston University. She co-directs the Harvard Medical School Fellowship in Pharmaceutical Policy Research and leads the global Medicines and Insurance Coverage (MedIC) Initiative on behalf of the WHO CCPP.
Dr. Wagner conducts research to inform evidence-based policy decisions that improve access to and use of medicines for vulnerable populations in the United States and particularly in developing countries. Current domestic research includes an analysis funded by The Commonwealth Fund to estimate the affordability of health care and medicines among Americans age 50 to 65 years old. Current international projects include studies to develop an outpatient benefit to cover medicines for members of the Philippine Health Insurance Corporation. Her teaching activities focus on building capacity in insurance systems to design, implement, and evaluate medicines benefit policies. Together with Dr. Dennis Ross-Degnan, she developed the curriculum for the first MedIC Course on Medicines Policy Analysis for Health and Insurance Systems, held in Manila in September 2007.
Dr. Wagner received her Master of Public Health degree and a doctorate in epidemiology from Harvard School of Public Health. She also holds a doctorate in clinical pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences and is licensed to practice pharmacy in Germany and Massachusetts.
Selected publications:
- Wagner AK, Soumerai SS, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapeutics 2002;27:299-309.
- Wagner AK, Ross-Degnan D, Gurwitz JH, Zhang F, Gilden DB, Cosler L, et al. Effect of New York State regulatory action on benzodiazepine prescribing and hip fracture rates. Ann Intern Med. 2007;146:96-103.
- Wagner AK, Chan KA, Dashevsky I, Raebel MA, Andrade SE, Elston Lafata J, Davis RL, Gurwitz JH, Soumerai SB, Platt R. FDA Drug Prescribing Warnings: Is the Black Box Half Empty or Half Full? Pharmacoepidemiology and Drug Safety 2005; published online in Wiley Interscience at www.interscience.wiley.com on November 18, 2005.
- Wagner AK, Zhang F, Soumerai SB, Walker AM, Gurwitz JH, Glynn RJ, Ross-Degnan D. Benzodiazepine use and hip fractures in the elderly: Who is at greatest risk? Archives of Internal Medicine 2004; 164:1567-1572.
- Wagner AK, Ross-Degnan D. The potential for insurance systems to increase access to and appropriate use of medicines in Asia-Pacific countries. Under review.
- Wagner AK, Valera M, Laviña S, Ross-Degnan D. Costs of hospital care for hypertension in an insured population without an outpatient medicines benefit: an observational study in the Philippines. Under review.
|
|
